ASCO 2023 | Tackling disease progression whilst using PARP inhibitors for prostate cancer

David James VanderWeele, MD, PhD, Feinberg School of Medicine, Chicago, IL, explains how research is focused on earlier disease states using combination studies in the castration-resistant prostate cancer (CRPC) setting. In both localized and metastatic scenarios, cure rates can be improved through earlier exposure to PARP inhibitors in a biomarker-chosen or sensitization to radiotherapy setting. If patients progress onPARP inhibitors, select patients may benefit from the use of platinum agents. Research into mechanisms of resistance relating to PARP inhibitors remains in its infancy, however reversion mutations have been seen in select patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.